These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22884661)

  • 21. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
    Callendret B; Vellinga J; Wunderlich K; Rodriguez A; Steigerwald R; Dirmeier U; Cheminay C; Volkmann A; Brasel T; Carrion R; Giavedoni LD; Patterson JL; Mire CE; Geisbert TW; Hooper JW; Weijtens M; Hartkoorn-Pasma J; Custers J; Grazia Pau M; Schuitemaker H; Zahn R
    PLoS One; 2018; 13(2):e0192312. PubMed ID: 29462200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal immunization with recombinant Vaccinia virus Tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice.
    Xie L; Zai J; Yi K; Li Y
    Vaccine; 2019 May; 37(25):3335-3342. PubMed ID: 31076161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AAV-expressed G protein induces robust humoral and cellular immune response and provides durable protection from rabies virus challenges in mice.
    Liu C; Li J; Yao Q; Gao Z; Cheng Y; Zhou M; Tang Y; Sun L; Dai J; Cao G; Zhang XL; Zhang R
    Vet Microbiol; 2020 Mar; 242():108578. PubMed ID: 32122589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Open-label phase I clinical trial of Ad5-EBOV in Africans in China.
    Wu L; Zhang Z; Gao H; Li Y; Hou L; Yao H; Wu S; Liu J; Wang L; Zhai Y; Ou H; Lin M; Wu X; Liu J; Lang G; Xin Q; Wu G; Luo L; Liu P; Shentu J; Wu N; Sheng J; Qiu Y; Chen W; Li L
    Hum Vaccin Immunother; 2017 Sep; 13(9):2078-2085. PubMed ID: 28708962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal vaccination with ebola virus GP amino acids 258-601 protects mice against lethal challenge.
    Su QD; He SH; Yi Y; Qiu F; Lu XX; Jia ZY; Meng QL; Fan XT; Tian RG; Audet J; Qiu XG; Bi SL
    Vaccine; 2018 Oct; 36(41):6053-6060. PubMed ID: 30195490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection.
    Warfield KL; Olinger G; Deal EM; Swenson DL; Bailey M; Negley DL; Hart MK; Bavari S
    J Immunol; 2005 Jul; 175(2):1184-91. PubMed ID: 16002721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species.
    Zahn R; Gillisen G; Roos A; Koning M; van der Helm E; Spek D; Weijtens M; Grazia Pau M; Radošević K; Weverling GJ; Custers J; Vellinga J; Schuitemaker H; Goudsmit J; Rodríguez A
    PLoS One; 2012; 7(12):e44115. PubMed ID: 23236343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
    Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
    J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.
    Williams KJ; Qiu X; Fernando L; Jones SM; Alimonti JB
    Viral Immunol; 2015 Feb; 28(1):51-61. PubMed ID: 25494457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetically Modified Rabies Virus Vector-Based Rift Valley Fever Virus Vaccine is Safe and Induces Efficacious Immune Responses in Mice.
    Zhang S; Hao M; Feng N; Jin H; Yan F; Chi H; Wang H; Han Q; Wang J; Wong G; Liu B; Wu J; Bi Y; Wang T; Sun W; Gao Y; Yang S; Zhao Y; Xia X
    Viruses; 2019 Oct; 11(10):. PubMed ID: 31597372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A rabies virus vectored severe fever with thrombocytopenia syndrome (SFTS) bivalent candidate vaccine confers protective immune responses in mice.
    Tian L; Yan L; Zheng W; Lei X; Fu Q; Xue X; Wang X; Xia X; Zheng X
    Vet Microbiol; 2021 Jun; 257():109076. PubMed ID: 33957572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge.
    Liu Y; Ye L; Lin F; Gomaa Y; Flyer D; Carrion R; Patterson JL; Prausnitz MR; Smith G; Glenn G; Wu H; Compans RW; Yang C
    Sci Rep; 2018 Jul; 8(1):11193. PubMed ID: 30046140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
    Wu S; Kroeker A; Wong G; He S; Hou L; Audet J; Wei H; Zhang Z; Fernando L; Soule G; Tran K; Bi S; Zhu T; Yu X; Chen W; Qiu X
    J Infect Dis; 2016 Oct; 214(suppl 3):S326-S332. PubMed ID: 27493239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
    Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.
    Li W; Ye L; Carrion R; Mohan GS; Nunneley J; Staples H; Ticer A; Patterson JL; Compans RW; Yang C
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S398-403. PubMed ID: 25877553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection.
    Cooper CL; Martins KA; Stronsky SM; Langan DP; Steffens J; Van Tongeren S; Bavari S
    Emerg Microbes Infect; 2017 Jun; 6(6):e46. PubMed ID: 28588288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.
    Wong G; Audet J; Fernando L; Fausther-Bovendo H; Alimonti JB; Kobinger GP; Qiu X
    Vaccine; 2014 Sep; 32(43):5722-9. PubMed ID: 25173474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.
    Marzi A; Ebihara H; Callison J; Groseth A; Williams KJ; Geisbert TW; Feldmann H
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1066-74. PubMed ID: 21987743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
    Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
    mBio; 2019 May; 10(3):. PubMed ID: 31138743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.
    Bounds CE; Kwilas SA; Kuehne AI; Brannan JM; Bakken RR; Dye JM; Hooper JW; Dupuy LC; Ellefsen B; Hannaman D; Wu H; Jiao JA; Sullivan EJ; Schmaljohn CS
    PLoS One; 2015; 10(9):e0137786. PubMed ID: 26422247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.